Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045444507> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2045444507 endingPage "642" @default.
- W2045444507 startingPage "635" @default.
- W2045444507 abstract "Nevirapine is a non-nucleoside reverse transcriptase inhibitor of HIV-1 which exhibits synergy in vitro with zidovudine (ZDV) and also is active against ZDV-resistant HIV. We evaluated the activity and safety of nevirapine in combination with ZDV in patients receiving long-term ZDV therapy.We conducted a randomized, open-label, controlled 28-week study of nevirapine (200 mg daily for 2 weeks followed by 200 mg twice daily for 26 weeks) and continued ZDV (500-600 mg daily) versus continued ZDV alone in 49 HIV-1 p24 antigenaemic patients with CD4+ lymphocyte counts < 500 x 10(6)/l and who had been treated with ZDV for at least 6 months.Addition of nevirapine to ZDV resulted in a significant and rapid reduction in circulating RNA load (mean, 0.65), a mean CD4+ lymphocyte rise of 34 x 10(6)/l, a reduction in serum beta 2-microglobulin and a median fall in immune complex dissociated p24 antigen levels of 69%. These changes remained statistically significant for 4, 4, 12 and at least 28 weeks, respectively. The principal adverse event due to nevirapine was a hypersensitivity reaction comprising rash with or without fever and mucositis in eight (32%) patients, which was dose-limiting in seven patients.Nevirapine exhibits significant although transient anti-HIV activity in ZDV-pretreated patients but its use is frequently associated with a hypersensitivity reaction." @default.
- W2045444507 created "2016-06-24" @default.
- W2045444507 creator A5036142555 @default.
- W2045444507 creator A5042386313 @default.
- W2045444507 creator A5044534970 @default.
- W2045444507 creator A5048537587 @default.
- W2045444507 creator A5050563833 @default.
- W2045444507 creator A5074256223 @default.
- W2045444507 creator A5075604032 @default.
- W2045444507 date "1996-06-01" @default.
- W2045444507 modified "2023-10-02" @default.
- W2045444507 title "A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients" @default.
- W2045444507 doi "https://doi.org/10.1097/00002030-199606000-00009" @default.
- W2045444507 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8780818" @default.
- W2045444507 hasPublicationYear "1996" @default.
- W2045444507 type Work @default.
- W2045444507 sameAs 2045444507 @default.
- W2045444507 citedByCount "76" @default.
- W2045444507 countsByYear W20454445072012 @default.
- W2045444507 countsByYear W20454445072013 @default.
- W2045444507 countsByYear W20454445072014 @default.
- W2045444507 countsByYear W20454445072022 @default.
- W2045444507 countsByYear W20454445072023 @default.
- W2045444507 crossrefType "journal-article" @default.
- W2045444507 hasAuthorship W2045444507A5036142555 @default.
- W2045444507 hasAuthorship W2045444507A5042386313 @default.
- W2045444507 hasAuthorship W2045444507A5044534970 @default.
- W2045444507 hasAuthorship W2045444507A5048537587 @default.
- W2045444507 hasAuthorship W2045444507A5050563833 @default.
- W2045444507 hasAuthorship W2045444507A5074256223 @default.
- W2045444507 hasAuthorship W2045444507A5075604032 @default.
- W2045444507 hasConcept C126322002 @default.
- W2045444507 hasConcept C142462285 @default.
- W2045444507 hasConcept C197934379 @default.
- W2045444507 hasConcept C203014093 @default.
- W2045444507 hasConcept C2776452011 @default.
- W2045444507 hasConcept C2777351918 @default.
- W2045444507 hasConcept C2778570526 @default.
- W2045444507 hasConcept C2779130552 @default.
- W2045444507 hasConcept C2780216070 @default.
- W2045444507 hasConcept C2780727368 @default.
- W2045444507 hasConcept C2993143319 @default.
- W2045444507 hasConcept C3013748606 @default.
- W2045444507 hasConcept C71924100 @default.
- W2045444507 hasConcept C90924648 @default.
- W2045444507 hasConceptScore W2045444507C126322002 @default.
- W2045444507 hasConceptScore W2045444507C142462285 @default.
- W2045444507 hasConceptScore W2045444507C197934379 @default.
- W2045444507 hasConceptScore W2045444507C203014093 @default.
- W2045444507 hasConceptScore W2045444507C2776452011 @default.
- W2045444507 hasConceptScore W2045444507C2777351918 @default.
- W2045444507 hasConceptScore W2045444507C2778570526 @default.
- W2045444507 hasConceptScore W2045444507C2779130552 @default.
- W2045444507 hasConceptScore W2045444507C2780216070 @default.
- W2045444507 hasConceptScore W2045444507C2780727368 @default.
- W2045444507 hasConceptScore W2045444507C2993143319 @default.
- W2045444507 hasConceptScore W2045444507C3013748606 @default.
- W2045444507 hasConceptScore W2045444507C71924100 @default.
- W2045444507 hasConceptScore W2045444507C90924648 @default.
- W2045444507 hasIssue "6" @default.
- W2045444507 hasLocation W20454445071 @default.
- W2045444507 hasLocation W20454445072 @default.
- W2045444507 hasOpenAccess W2045444507 @default.
- W2045444507 hasPrimaryLocation W20454445071 @default.
- W2045444507 hasRelatedWork W2045444507 @default.
- W2045444507 hasRelatedWork W2073421051 @default.
- W2045444507 hasRelatedWork W2081669572 @default.
- W2045444507 hasRelatedWork W2088282011 @default.
- W2045444507 hasRelatedWork W2090130046 @default.
- W2045444507 hasRelatedWork W2109940476 @default.
- W2045444507 hasRelatedWork W2135892517 @default.
- W2045444507 hasRelatedWork W2146986579 @default.
- W2045444507 hasRelatedWork W2382765468 @default.
- W2045444507 hasRelatedWork W2412482761 @default.
- W2045444507 hasVolume "10" @default.
- W2045444507 isParatext "false" @default.
- W2045444507 isRetracted "false" @default.
- W2045444507 magId "2045444507" @default.
- W2045444507 workType "article" @default.